3bigs, a Korean bio-venture, said Friday that it would develop a bio-health big data platform for drug development and genome therapy in collaboration with Amazon Web Services (AWS).

3bigs will cooperate with Amazon Web Services to establish a bio-health big data platform.
3bigs will cooperate with Amazon Web Services to establish a bio-health big data platform.

According to the company, the bio-health big data platform will combine patient data and genomic data of major hospitals in Busan, Korea’s second-largest city, using AWS services that provide access control to patient information, allowing doctors and diagnostic labs to search share clinical reports safely.

Under the accord, 3bigs plans to develop a research platform for drug development and genome therapy by actively utilizing AWS services for integrated bio-health information and disease linkage analysis, using hospital patient data and genomic data. Through this, major hospitals in Busan, including Pusan ​​National University Hospital, will find accurate treatment methods for cancer patients and patients with rare diseases, the company said.

The platform allows data from patients with genomic mutations similar to or identical to those of the patient and clinical results derived from chemotherapy for new drug development. Also, it can reduce various side effects by identifying side effects that do not match the patient's genetic information during chemotherapy or the risk of using other medical drugs.

AWS will assist 3bigs in proposing a cloud-based genome research platform to the Korean government using its service's secure, cost-effective, and flexible research environment and support 3bigs in transferring its genome research solution to the AWS Cloud.

"By using AWS's broad and in-depth services with the highest security standards, we will develop bio-health solutions to improve healthcare," 3bigs CEO Park Joon-hyung said. "Our expertise will contribute to bio-health projects at home and abroad and vitalization of the future healthcare industry."ㅇ

Copyright © KBR Unauthorized reproduction, redistribution prohibited